NFE2L2 and Parkinson disease: The activation of Nrf2 through its activator or the inhibition of C/EBPβ using C/EBPβ‐HDO can effectively reduce the degeneration of dopaminergic neurons in mouse models of PD by decreasing abnormal α‐Syn expression levels.